Amylyx Pharmaceuticals, Inc. (AMLX) stock
AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$27.52−0.28 (-1.01%)
Close on Nov 17, 2026Market cap $3.07BP/E –Yield –
Amylyx Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Amylyx Pharmaceuticals's revenue for the twelve months ending Dec 31, 2025 was $0. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $380.79M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $87.37M | -77.1% |
| FY2023 | Dec 31, 2023 | $380.79M | +1612.9% |
| FY2022 | Dec 31, 2022 | $22.23M | +7700.0% |
| FY2021 | Dec 31, 2021 | $285.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $416.00K | -99.6% |
| Q2 FY2024 | Jun 30, 2024 | -$1.02M | -101.0% |
| Q1 FY2024 | Mar 31, 2024 | $88.64M | +24.1% |
| Q4 FY2023 | Dec 31, 2023 | $108.45M | +395.5% |
| Q3 FY2023 | Sep 30, 2023 | $102.69M | +29666.1% |
| Q2 FY2023 | Jun 30, 2023 | $98.22M | – |
| Q1 FY2023 | Mar 31, 2023 | $71.43M | +24962.5% |
| Q4 FY2022 | Dec 31, 2022 | $21.89M | – |
| Q3 FY2022 | Sep 30, 2022 | $345.00K | – |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q3 FY2021 | Sep 30, 2021 | $285.00K | – |
See a number that looks wrong?